Clinical Trials
27 trialsSVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
University of Miami
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
University of Florida
Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors
H. Lee Moffitt Cancer Center and Research Institute
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
Ohio State University Comprehensive Cancer Center
NET-PRO
University of Iowa
NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas
Case Comprehensive Cancer Center
REBORN
University of Roma La Sapienza
JPET2Clinic
Jagiellonian University
P-PRRT
CHU de Quebec-Universite Laval
CABONEN
University Medical Center Goettingen
Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients
Rigshospitalet, Denmark
YOUNGSTER
European Institute of Oncology
RAPNEN
Catholic University of the Sacred Heart
Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms
Rigshospitalet, Denmark
TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors
Asan Medical Center
A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours
Fundación de investigación HM
AveNEC
Johannes Gutenberg University Mainz
Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm
Peking Union Medical College Hospital
Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma
Peking Union Medical College Hospital
MONET
European Institute of Oncology
EVINEC
AIO-Studien-gGmbH
Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors
Yale University
68Ga
Vanderbilt-Ingram Cancer Center
P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome
H. Lee Moffitt Cancer Center and Research Institute
68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
Ochsner Health System
XELBEVOCT
University of Turin, Italy
5FU and Octreotide Long-acting Release (LAR) for Neuroendocrine Tumors
University of Turin, Italy